- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03103243
Pilot Study to Investigate Contemplative Intervention in Lupus Patients (LUPP)
March 12, 2019 updated by: University of Virginia
A Pilot Study to Investigate a Contemplation-Based Intervention and Health Outcomes in Systemic Lupus Erythematosus Patients
The study tests whether contemplative-based intervention can modify pathogenic processes in participants with Lupus.
Techniques such as meditation, mindfulness and yoga may have an impact on the disease and may decrease psychological distress, increase self-regulation capabilities, and reduce pain.
Additionally, incorporating patients' caregivers may strengthen their relationships and, thereby, improve their health and well-being.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objective of this pilot study is to test the feasibility of an innovative contemplative-based and caregiver-inclusive intervention can modify pathogenic processes in systemic lupus erythematosus (SLE).
Contemplative techniques such as meditation, mindfulness and yoga may have an impact on the disease burden and may decrease psychological distress, increase self-regulation capabilities, and reduce pain.
Research also suggests that contemplative practices, such as an intensive mindfulness intervention, may have a direct effect on the underlying disease process itself by altering epigenetic control of gene expression, decreasing proinflammatory cytokine production and reestablishing immunologic homeostasis.
It is also well documented that social relationships moderate physical health.
Incorporating patients' caregivers may strengthen their relationships and thereby improve their health and well-being.
It is anticipated that the successful outcome of the intervention described in this proposal will provide the basis for a new and effective contemplative-based and caregiver-inclusive therapy for SLE and other rheumatic diseases.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females who have given written informed consent
- 18 and older
- Literate in English: able to read, understand, follow instructions, and complete the rating scales and questionnaires accurately
- Have a clinical diagnosis of systemic lupus erythematosus
- Must pass the initial MRI screening administered over the phone
- Inclusion criteria for support person: must be able to attend sessions with SLE patient.
Exclusion Criteria:
- Significant previous mindfulness training and experience (e.g. MBSR course, daily meditation practice)
- Any current Axis I DSM-IV-TR psychiatric disorder that, in the clinician's opinion, warrants treatment or would preclude safe participation in the protocol, including, but not limited to: psychosis, schizophrenia, dementia, schizotypal personality disorder, borderline personality disorder, bipolar disorder, primary diagnosis of eating disorder, or chronic suicidality or homicidality.
- Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not related to SLE (i.e., diabetes, cardiovascular, pulmonary, hematologic, gastrointestinal, neurological, or infectious) which, in the opinion of the treating physician, could confound the results of the study or put the patients at undue risk
- Chronic use of prescribed or recreational psychoactive drugs (self-reported)
- Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Baseline (self-reported)
- Diagnosis of lupus for over 20 years
- Too sick to meaningfully participate (e.g. hospitalized, flaring at the time of screening)
- In order to participate in the MRI portion of the study, participants must pass the in-person MRI screening administered by the MRI technician before each MRI. If participants fail the in-person MRI screening, they will be excluded from the MRI portion of the study, but can still participate in the intervention and blood draw portions of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Intervention
This is a single arm trial.
All participants will be administered two baseline fMRIs and blood analysis prior to participation in a mindfulness group and individual mindfulness intervention sessions.
A post intervention fMRI and blood analysis will complete the trial participation.
|
In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in blood
Time Frame: Baseline Assessment, within 2 weeks prior to intervention, within 2 weeks after intervention
|
Number of participants with abnormal lab values (Complete Blood Count, Chemistry Panel, Autoantibodies, Complement C3 & C4, Cytokines)
|
Baseline Assessment, within 2 weeks prior to intervention, within 2 weeks after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in brain activity during functional MRI
Time Frame: Baseline Assessment, within 2 weeks prior to intervention, within 2 weeks after intervention
|
Number of participants with change in brain activity during functional MRI tasks (Handholding, Balloon Analog Risk Task, Penn Emotion Recognition Task, Operation Span Task, Resting State Task)
|
Baseline Assessment, within 2 weeks prior to intervention, within 2 weeks after intervention
|
Change from baseline in Patient Reported Outcomes
Time Frame: Baseline Assessment, within 2 weeks prior to intervention, throughout the 6-week intervention, within 2 weeks after intervention
|
Patient-reported change in health and symptoms
|
Baseline Assessment, within 2 weeks prior to intervention, throughout the 6-week intervention, within 2 weeks after intervention
|
Change from baseline in SLE disease activity
Time Frame: Baseline Assessment, within 2 weeks prior to intervention, within 2 weeks after intervention
|
Systemic Lupus Activity Questionnaire (SLAQ)
|
Baseline Assessment, within 2 weeks prior to intervention, within 2 weeks after intervention
|
Change from baseline in psychosocial function
Time Frame: Baseline Assessment, within 2 weeks prior to intervention, throughout the 6-week intervention, within 2 weeks after intervention
|
Self reported psychosocial function
|
Baseline Assessment, within 2 weeks prior to intervention, throughout the 6-week intervention, within 2 weeks after intervention
|
Change from baseline in Heart Rate Variability
Time Frame: Throughout the entire 6-week intervention
|
Collected using emWave device
|
Throughout the entire 6-week intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: James A Coan, Ph.D., University of Virginia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 27, 2017
Primary Completion (ACTUAL)
June 4, 2018
Study Completion (ACTUAL)
June 4, 2018
Study Registration Dates
First Submitted
March 22, 2017
First Submitted That Met QC Criteria
March 30, 2017
First Posted (ACTUAL)
April 6, 2017
Study Record Updates
Last Update Posted (ACTUAL)
March 14, 2019
Last Update Submitted That Met QC Criteria
March 12, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19671
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lupus Erythematosus, Systemic
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...CompletedSystemic Lupus Erythematosus | Cutaneous Lupus ErythematosusSpain, Bulgaria, Germany, Moldova, Republic of, North Macedonia, Ukraine
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
Clinical Trials on Mindfulness Based Group Sessions
-
Lund UniversityCompleted
-
University of HelsinkiTechnische Universität Dresden; University of Cambridge; University of JyvaskylaUnknownStress | Well-being | Mindfulness | Functional AbilityFinland
-
Stanford UniversityCompletedObesityUnited States
-
Humboldt-Universität zu BerlinComisión Nacional de Investigación Científica y TecnológicaUnknownStress, Psychological | Emotional Stress | Mindfulness | Social CognitionGermany
-
Charite University, Berlin, GermanyBrain & Behavior Research FoundationRecruitingSchizophrenia Spectrum and Other Psychotic DisordersGermany
-
United States Department of DefenseActive, not recruiting
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong Kong; Jilin Medical College, China; Taipei Medical University...CompletedSchizophreniaHong Kong, China, Taiwan
-
Duzce UniversityCompletedStress | Depression, Anxiety | Mindfulness | Nursing StudentsTurkey
-
Gazi UniversityCompletedSocial Anxiety | Self Confidence | AssertivenessTurkey
-
University of MiamiRecruitingStressUnited States